Today's Veterinary Practice

JUL-AUG 2014

Today's Veterinary Practice provides comprehensive information to keep every small animal practitioner up to date on companion animal medicine and surgery as well as practice building and management.

Issue link: http://todaysveterinarypractice.epubxp.com/i/354788

Contents of this Issue

Navigation

Page 38 of 83

VETORYL CAPSULES are the only FDA veterinary-approved treatment for pituitary-dependent and adrenal-dependent hyperadrenocorticism. Available in 10 mg, 30 mg, 60 mg, and 120mg capsules! VETORYL CAPSULES contain the active ingredient trilostane, which blocks the excessive production of cortisol. Daily administration of VETORYL CAPSULES can greatly reduce the clinical signs associated with Cushing's Syndrome, enhancing the quality of life for both dog and owner. For more information, call Dechra's Technical Support Team at 866-933-2472 or visit www.Dechra-US.com. Contact your veterinary distributor to order VETORYL CAPSULES today! VETORYL is a trademark of Dechra LTD. ©2009, Dechra Ltd. NADA 141-291, Approved by FDA As with all drugs, side effects may occur. In fi eld studies, the most common side effects reported were poor/reduced appetite, vomiting, lethargy, diarrhea, and weakness. Occasionally, more serious side effects including severe depression, hemorrhagic diarrhea, collapse, hypoadrenocortical crisis, or adrenal necrosis/rupture may occur, and may result in death. VETORYL CAPSULES are not for use in dogs with primary hepatic or renal disease, or in pregnant dogs. Refer to the prescribing information for complete details or visit www.dechra-us.com. VETORYL ® CAPSULES (trilostane) are available in 10 mg, 30 mg, 60 mg, and 120 mg Capsules ! What do dogs who take VETORYL CAPSULES (trilostane) have in common? Results like these. Effective treatment for Cushing's Syndrome is FDA approved for dogs of any size. with VETORYL ® with VETORYL ® VETORYL ®

Articles in this issue

Links on this page

Archives of this issue

view archives of Today's Veterinary Practice - JUL-AUG 2014